Vyleesi (PT-141) for Women's Libido and HSDD: What the Label and Trials Actually Show

Most of what circulates about "PT-141 for women" mixes two different things together: a real FDA-approved drug with a real Phase 3 trial program, and a broader compounding-market product sold under the same research name for a much wider set of claims. This article is about the first one specifically — Vyleesi, brand-name bremelanotide, approved for one diagnosis in one population — read directly off its own label and its own trial publications, without folding in the mechanism deep-dive or the male-use evidence question our companion article, PT-141: What the Evidence Actually Shows, already covers in depth. What's different here is the frame: this is the drug as it was actually approved, for the person it was actually approved for, and — a fact worth stating plainly rather than leaving implied — a product with no ranked provider on this site's boards.

What HSDD actually is

Hypoactive sexual desire disorder is a specific clinical diagnosis, not a casual synonym for "low libido." It's defined as a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked personal distress or interpersonal difficulty⁵ — the distress requirement matters, because a woman with low desire who isn't bothered by it doesn't meet the definition. The diagnosis also explicitly excludes cases better explained by something else: a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or substance¹. It's also common enough to be a mainstream women's-health issue rather than a rare condition — a clinical review estimates HSDD affects roughly 1 in 10 adult women in the United States, with similar prevalence reported in Europe⁵. The same review frames desire itself as a brain-level balance between excitatory signals (dopamine, estrogen, testosterone) and inhibitory ones (serotonin, prolactin, opioids) — low desire can come from too little of the first, too much of the second, or both⁵, which is the same central-nervous-system framing behind bremelanotide's own proposed mechanism, covered in full in our companion article.

What Vyleesi is approved for, exactly

Vyleesi (bremelanotide, NDA 210557) was approved by the FDA on June 21, 2019, sponsored by Cosette Pharmaceuticals⁴. Its label's own indications-and-usage language is specific, not a general "female sexual dysfunction" catch-all: "treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)," where "acquired" means the low desire developed after a period of normal desire (not lifelong) and "generalized" means it isn't limited to one partner or situation¹. The label states directly that it is not indicated for postmenopausal women, for men, or for sexual performance enhancement generally¹. It ships as a pre-filled 1.75 mg/0.3 mL autoinjector, self-administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a hard ceiling of one dose per 24 hours and no more than 8 doses per month².

What the RECONNECT trials actually found

Vyleesi's approval rests on two identical, randomized, double-blind, placebo-controlled Phase 3 trials — RECONNECT studies 301 and 302 — that together randomized 1,267 premenopausal women with acquired, generalized HSDD (1,202 in the efficacy analysis; 85.6% white, mean age 39, 96.6% U.S. sites) to 24 weeks of self-administered bremelanotide 1.75 mg as needed, or placebo⁶. The trials' co-primary endpoints, read directly from the published results as differences from placebo, were consistent across both individual trials and the integrated analysis:

Both endpoints reached statistical significance in both trials individually and in the pooled analysis⁶. This is a real, adequately powered, twice-replicated trial result — and it is specific to exactly the population it enrolled. Nothing about these numbers describes what bremelanotide does for a woman without an HSDD diagnosis, in men, or after menopause, because the trials weren't designed to answer those questions.

What the label's own safety data show

Vyleesi's Section 6.1 clinical-trials-experience table, read directly from the current label rather than a secondary summary, reports adverse reactions in the pooled Phase 3 population (627 bremelanotide-treated vs. 620 placebo-treated patients) at 2% incidence or higher:

Three warnings, read in the label's own words, are worth more than the incidence table alone conveys:

Nausea (Section 5.3). The label states nausea was reported in 40% of treated patients, required anti-emetic therapy in 13%, and led to premature discontinuation in 8% — but also notes it "improves for most patients with the second dose," and a company-sponsored attempt to prevent it with ondansetron pretreatment specifically was not effective.

Focal hyperpigmentation (Section 5.2). Reported in 1% of patients on the approved up-to-8-doses-per-month schedule, involving the face, gums, or breasts, versus none on placebo — with a higher rate in patients with darker skin, and the label states resolution "was not confirmed in all patients after discontinuation," meaning some cases may not fully reverse.

Transient blood pressure and heart rate changes (Section 5.1). Maximal increases of 6 mmHg systolic and 3 mmHg diastolic blood pressure, alongside a heart-rate reduction up to 5 beats per minute, peaking 2 to 4 hours post-dose and typically resolving within 12 hours — the basis for Vyleesi's contraindication in patients with uncontrolled hypertension or known cardiovascular disease.

A separate, smaller safety note is worth including precisely because it parallels a fact this site's readers may already know from a different drug entirely: Vyleesi's own label advises effective contraception during use and discontinuation if pregnancy is suspected. Across trials of over 1,057 treated patients, 7 pregnancies were reported — 1 spontaneous abortion, 5 full-term live births, and 1 lost to follow-up, with no major congenital anomalies among them — a number the label itself calls too small to determine whether there's a drug-associated risk³. That's a different mechanism and a different reason than the oral-contraceptive-absorption interaction our tirzepatide birth control and PCOS fertility article covers, but the practical instruction rhymes: know your own contraceptive situation and discuss it with whoever prescribes you either drug, rather than assuming it's been covered.

Vyleesi vs. compounded PT-141: not the same delivery, same molecule

One distinction is easy to lose in casual conversation about "PT-141": Vyleesi ships as a pre-filled autoinjector the patient never reconstitutes, while the compounded "PT-141" sold by peptide vendors is sterile lyophilized powder in a vial that the buyer mixes with bacteriostatic water before drawing a dose¹. Our companion article covers that distinction, the evidence for off-label male use, and the full mechanism picture in depth — read PT-141: What the Evidence Actually Shows for that side of the story. If you're specifically trying to work out a reconstituted dose, our PT-141 calculator does that arithmetic; it has no bearing on whether what's in the vial matches what the label above describes, since the FDA review behind these numbers covers only the approved autoinjector product.

Why this article has no board, no ranked provider, and no affiliate link

This site ranks compounded-pharmacy providers by what they actually sell — tirzepatide, semaglutide, sermorelin, and the peptides those providers' own intake forms name. Vyleesi is different in a way worth stating outright rather than leaving unaddressed: it's an FDA-approved product filled by a licensed retail or specialty pharmacy against a prescription, not a compounded peptide any provider on this site's roster carries. No roster provider prescribes or dispenses Vyleesi specifically, so there is no honest board entry, ranked card, or affiliate relationship to attach to this article — the same reason our epitalon, KPV, and DSIP articles carry no board tie-in either. If you have an HSDD diagnosis and are considering Vyleesi, that's a conversation for an OB-GYN or a prescriber who can evaluate the diagnosis criteria above, not a purchase decision this site is set up to help you make.